Nice but sudden cardiac death is not an annual event.
RT @SABOURETCardio: Are #PCSK9i cost effective ? Kind reminder of the article by @DLBHATTMD et al ☀️ https://t.co/ayAv45kKxV https://t.co/q…
RT @SABOURETCardio: Are #PCSK9i cost effective ? Kind reminder of the article by @DLBHATTMD et al ☀️ https://t.co/ayAv45kKxV https://t.co/q…
RT @SABOURETCardio: Are #PCSK9i cost effective ? Kind reminder of the article by @DLBHATTMD et al ☀️ https://t.co/ayAv45kKxV https://t.co/q…
RT @SABOURETCardio: Are #PCSK9i cost effective ? Kind reminder of the article by @DLBHATTMD et al ☀️ https://t.co/ayAv45kKxV https://t.co/q…
Are #PCSK9i cost effective ? Kind reminder of the article by @DLBHATTMD et al ☀️ https://t.co/ayAv45kKxV https://t.co/q9pwCq4aao
@ESC_Journals @cpgale3 @diogoasantosfer Is this cost effective though? that is initiating at these low LDL-C levels. https://t.co/8kFHSpA0Vo.
RT @cpcannon: ODYSSEY OUTCOMES Cost effectiveness data. Better in patients with LDL-C >100 mg/dl. https://t.co/d816WAJdgl
RT @danielisazamd: Solo con LDL > 100 mg se llega al punto de costo-efectividad favorable con iPCSK9. Para pensarlo. Cost-Effectiveness of…
RT @danielisazamd: Solo con LDL > 100 mg se llega al punto de costo-efectividad favorable con iPCSK9. Para pensarlo. Cost-Effectiveness of…
RT @danielisazamd: Solo con LDL > 100 mg se llega al punto de costo-efectividad favorable con iPCSK9. Para pensarlo. Cost-Effectiveness of…
RT @danielisazamd: Solo con LDL > 100 mg se llega al punto de costo-efectividad favorable con iPCSK9. Para pensarlo. Cost-Effectiveness of…
Solo con LDL > 100 mg se llega al punto de costo-efectividad favorable con iPCSK9. Para pensarlo. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes | JACC: Journal of the American College of Cardiology https://t.co/l1I6S0fxjw
RT @cpcannon: ODYSSEY OUTCOMES Cost effectiveness data. Better in patients with LDL-C >100 mg/dl. https://t.co/d816WAJdgl
RT @cpcannon: ODYSSEY OUTCOMES Cost effectiveness data. Better in patients with LDL-C >100 mg/dl. https://t.co/d816WAJdgl
ODYSSEY OUTCOMES Cost effectiveness data. Better in patients with LDL-C >100 mg/dl. https://t.co/d816WAJdgl
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes | JACC: Journal of the American College of Cardiology https://t.co/8oTtok4h5L
RT @JACCJournals: Is #PCSK9i treatment a cost-effective strategy for patients with recent #cvACS on statins? Drs. @GabrielSteg, @DLBhattMD…
RT @krychtiukmd: Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular ou…
RT @krychtiukmd: Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular ou…
RT @JACCJournals: Is #PCSK9i treatment a cost-effective strategy for patients with recent #cvACS on statins? Drs. @GabrielSteg, @DLBhattMD…
RT @JACCJournals: Is #PCSK9i treatment a cost-effective strategy for patients with recent #cvACS on statins? Drs. @GabrielSteg, @DLBhattMD…
RT @JACCJournals: Is #PCSK9i treatment a cost-effective strategy for patients with recent #cvACS on statins? Drs. @GabrielSteg, @DLBhattMD…
RT @JACCJournals: Is #PCSK9i treatment a cost-effective strategy for patients with recent #cvACS on statins? Drs. @GabrielSteg, @DLBhattMD…
Is #PCSK9i treatment a cost-effective strategy for patients with recent #cvACS on statins? Drs. @GabrielSteg, @DLBhattMD and the ODYSSEY OUTCOMES investigators explore in this #JACC study: https://t.co/ybXW1pBBu6 https://t.co/oew66hnHaz
RT @SABOURETCardio: Cost-Effectiveness of Alirocumab in Patients With ACS | JACC #PCSK9i Target : pts with a LDLC > 100 mg/dL at baseline u…
RT @SABOURETCardio: Cost-Effectiveness of Alirocumab in Patients With ACS | JACC #PCSK9i Target : pts with a LDLC > 100 mg/dL at baseline u…
RT @krychtiukmd: Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular ou…
RT @krychtiukmd: Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular ou…
RT @krychtiukmd: Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular ou…
RT @krychtiukmd: Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular ou…
Alirocumab cost-effectiveness analysis in @JACCJournals based on ODYSSEY OUTCOMES: Alirocumab improves cardiovascular outcomes at costs considered good value in ACS patients with baseline LDL-C ≥100 mg/dl despite high intensity statin treatment https://
RT @SABOURETCardio: Cost-Effectiveness of Alirocumab in Patients With ACS | JACC #PCSK9i Target : pts with a LDLC > 100 mg/dL at baseline u…
RT @SABOURETCardio: Cost-Effectiveness of Alirocumab in Patients With ACS | JACC #PCSK9i Target : pts with a LDLC > 100 mg/dL at baseline u…
Also great audio summary @FusterValentin @JACCJournals @SABOURETCardio #cardiotwitter
RT @SABOURETCardio: Cost-Effectiveness of Alirocumab in Patients With ACS | JACC #PCSK9i Target : pts with a LDLC > 100 mg/dL at baseline u…
Cost-Effectiveness of Alirocumab in Patients With ACS | JACC #PCSK9i Target : pts with a LDLC > 100 mg/dL at baseline under #LLT @DLBHATTMD https://t.co/w6WeML99HY
RT @JACCJournals: For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with…
RT @JACCJournals: For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with…
RT @JACCJournals: For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with…
RT @JACCJournals: For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with…
RT @JACCJournals: For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with…
RT @JACCJournals: For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with…
For recent #cvACS patients on optimized statins, alirocumab improves #CVD outcomes with economic value for patients with LDL-C ≥100 mg/dl. https://t.co/ybXW1pBBu6 #JACC @DLBhattMD @gabrielsteg https://t.co/s5taN5qL2t
RT @mirvatalasnag: #CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based o…
RT @mirvatalasnag: #CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based o…
RT @mirvatalasnag: #CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based o…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @mirvatalasnag: #CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based o…
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes | JACC: Journal of the American College of Cardiology https://t.co/8oTtok4h5L
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @mirvatalasnag: #CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based o…
RT @mirvatalasnag: #CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based o…
#CostEffectiveness of PCSK9I 🔸Overall: $92,200/QALY 🔸$41,800 if LDL-C ≥100 mg/dl 🔸$299,400 if LDL-C <100 mg/dl 🔸Based on #OdysseyOutcomes ACS pts 🔸⬇️Economic value LDL-C <100 ❗️ Clinical value ⬇️MACE w alirocumab vs placebo 9.5% vs 11.1% HR,0.85,C
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @RenatoDLopes1: Important paper led by my friend Deepak Bhatt. Worth reading.
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @RenatoDLopes1: Important paper led by my friend Deepak Bhatt. Worth reading.
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
Important paper led by my friend Deepak Bhatt. Worth reading.
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
RT @DLBHATTMD: Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by…
Our late-breaking trial presentation on ODYSSEY Economics is now published in @JACCJournals with an insightful editorial by Drs. Weintraub and @webmd11 https://t.co/WqtdTSPSCm @gabrielsteg @DLBHATTMD @HeartBobH @TheMahaf @MTRHeart @RenatoDLopes1 #cardiotw